Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
J Genet Couns. 2023 Apr;32(2):342-350. doi: 10.1002/jgc4.1641. Epub 2022 Oct 17.
Germline genetic testing for inherited cancer risk is increasingly being performed with multigene panel testing with MUTYH often included on colorectal cancer- and polyposis-focused panels, as well as on broader pan-cancer panels. With up to 1%-2% of the general population being monoallelic MUTYH carriers, pathogenic/likely pathogenic (P/LP) variants in MUTYH are one of the most common findings on multigene cancer panels. However, little is known about patient experience and understanding of monoallelic MUTYH P/LP variants, nor whether such findings influence medical management recommendations and familial communication, which this study aims to better understand. Monoallelic P/LP MUTYH carriers were recruited from the Prospective Registry of Multiplex Testing (PROMPT) and completed a cross-sectional self-report survey on sociodemographic characteristics, medical and family history, experiences with MUTYH genetic testing, genetics and MUTYH knowledge, perceived cancer risk, and familial communication. Of 115 eligible PROMPT participants, 49 (43%) completed the survey who were primarily female (94%), white (96%), had a history of cancer (61%), and a median age of 51.4 years. Most participants (61%) reported satisfaction with how their healthcare provider managed their genetic test result and care, and 65% of survey participants reported their provider recommended colonoscopy based on their genetic test results. Participants' responses also reflected variable levels of knowledge regarding cancer risks and screening recommendations for MUTYH carriers. The majority (98%) of participants shared their genetic test results with at least some of their relatives; however, only 13% of eligible relatives reportedly underwent cascade testing. Taken together, this study provides needed insight into the overall experiences of monoallelic MUTYH carriers and highlights numerous areas for improvement in clinician education, communication, and management of these individuals.
种系基因检测在遗传性癌症风险中的应用日益广泛,多基因panel 检测越来越多地被应用,其中 MUTYH 通常被包括在结直肠癌和息肉病相关的 panel 中,也包括更广泛的泛癌 panel 中。由于多达 1%-2%的普通人群是单等位基因 MUTYH 携带者,因此 MUTYH 的致病性/可能致病性 (P/LP) 变体是多基因癌症 panel 中最常见的发现之一。然而,人们对单等位基因 MUTYH P/LP 变体的患者体验和理解知之甚少,也不知道这些发现是否会影响医学管理建议和家族沟通,本研究旨在更好地了解这些问题。单等位基因 P/LP MUTYH 携带者从前瞻性多重检测登记处 (PROMPT) 招募,并完成了一项关于社会人口统计学特征、医疗和家族史、MUTYH 基因检测体验、遗传学和 MUTYH 知识、感知癌症风险以及家族沟通的横断面自我报告调查。在 115 名符合条件的 PROMPT 参与者中,有 49 名(43%)完成了调查,他们主要是女性(94%)、白人(96%)、有癌症病史(61%),中位年龄为 51.4 岁。大多数参与者(61%)报告说对他们的医疗保健提供者管理他们的基因检测结果和护理的方式感到满意,65%的调查参与者报告说他们的提供者根据他们的基因检测结果建议进行结肠镜检查。参与者的回答也反映了他们对 MUTYH 携带者的癌症风险和筛查建议的知识水平存在差异。大多数(98%)参与者至少与部分亲属分享了他们的基因检测结果;然而,据报道,只有 13%的合格亲属进行了级联检测。总之,这项研究提供了对单等位基因 MUTYH 携带者总体体验的必要了解,并强调了在临床医生教育、沟通和管理这些个体方面有许多需要改进的地方。